CD274 and melanoma: The predictive value of PD-L1 expression on tumour infiltrating immune cells (TIIs) could explain the consistent finding that some patients with PD-L1 negative tumours still benefit from PD-1 pathway blockade, an effect which is especially pronounced in melanomas [57].